Acorda Therapeutics (NASDAQ:ACOR) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a research note issued to investors on Sunday. The brokerage issued a buy rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Price Performance

The stock has a market capitalization of $820,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.40. The company has a current ratio of 0.33, a quick ratio of 0.26 and a debt-to-equity ratio of 3.07. Acorda Therapeutics has a 12-month low of $0.61 and a 12-month high of $24.20. The firm has a 50-day moving average price of $10.56 and a 200 day moving average price of $11.97.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.